GLUTAMIC ACID ANTAGONIST

PURPOSE:To obtain a glutamic acid antagonist useful for treating neurodegenerative disorder, having low side effects, containing quinoxanine compound as an active ingredient. CONSTITUTION:A compound shown by the formula [R and R are H, halogen (with the proviso that a case where R and R are simultaneously H, Cl is omitted), 1-5C alkyl, 1-5C alkoxy, etc.; R and R are H, 1-5C alkyl, aryl, allyl, 3-7C cycloalkyl, etc.] is used as an active ingredient, properly blended with a commonly used carrier, excipient, binder, stabilizer, etc., and pharmaceutically manufactured by a conventional procedure to give the objective substance. The substance can be made into a dosage form such as tablet, capsule, syrup, suspension or injection, a dose is 1-100mg/day in the case of oral medication, 0.1-10mg in the case of perenteral administration and applied once to several times dividedly. (1H,4H)-6, 7-Dibromoquinoxaline-2,3-dione may be cited as the compound shown by the formula.